Originally published as JCO Early Release 10.1200/JCO.2008.17.2015 on October 14 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morschhauser, F. Articles by Hagenbeek, A. Search for Related Content PubMed PubMed Citation Articles by Morschhauser, F. Articles by Hagenbeek, A. Related Articles Related Article Related Editorial Social Bookmarking                            What's this?

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

Franck Morschhauser, John Radford, Achiel Van Hoof, Umberto Vitolo, Pierre Soubeyran, Herve Tilly, Peter C. Huijgens, Arne Kolstad, Francesco d’Amore, Marcos Gonzalez Diaz, Mario Petrini, Catherine Sebban, Pier Luigi Zinzani, Marinus H.J. van Oers, Wim van Putten, Angelika Bischof-Delaloye, Ama Rohatiner, Gilles Salles, Jens Kuhlmann, Anton Hagenbeek

From the Centre Hospitalier Universitaire, Lille; Institut Bergonié, Bordeaux; Centre Henri Becquerel, Rouen; Centre Léon Bérard, Lyon; Centre Hospitalier Lyon Sud, Pierre Bénite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology "Seràgnoli," University of Bologna, Bologna, Italy; VU University Medical Center; Academic Medical Center, Amsterdam; Erasmus University Medical Center/Dutch Hemato-Oncology Group (HOVON), Rotterdam; University Medical Center/HOVON, Utrecht, the Netherlands; The Norwegian Radium Hospital, Oslo, Norway; Århus University Hospital, Århus, Denmark; Hospital Clínico Universitario de Salamanca, Salamanca, Spain; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Bayer Schering Pharma AG, Berlin, Germany

Corresponding author: Anton Hagenbeek, MD, PhD, Department of Hematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands; e-mail: a.hagenbeek{at}umcutrecht.nl

Purpose We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 (⁹⁰Y)–ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission.

Patients and Methods Patients with CD20⁺ stage III or IV follicular lymphoma, who achieved a complete response (CR)/unconfirmed CR (CRu) or partial response (PR) after first-line induction treatment, were randomly assigned to receive ⁹⁰Y-ibritumomab tiuxetan (rituximab 250 mg/m² on day –7 and day 0 followed on day 0 by ⁹⁰Y-ibritumomab tiuxetan 14.8 MBq/kg; maximum of 1,184 MBq) or no further treatment (control). The primary end point was progression-free survival (PFS), which was calculated from the time of random assignment.

Results A total of 414 patients (consolidation, n = 208; control, n = 206) were enrolled at 77 centers. ⁹⁰Y-ibritumomab tiuxetan consolidation significantly prolonged median PFS (after a median observation time of 3.5 years) in all patients (36.5 v 13.3 months in control arm; hazard ratio [HR] = 0.465; P < .0001) and regardless of whether patients achieved PR (29.3 v 6.2 months in control arm; HR = 0.304; P < .0001) or CR/CRu (53.9 v 29.5 months in control arm; HR = 0.613; P = .0154) after induction treatment. Median PFS with consolidation was prolonged in all Follicular Lymphoma International Prognostic Index risk subgroups. After ⁹⁰Y-ibritumomab tiuxetan consolidation, 77% of patients in PR after induction converted to CR/CRu, resulting in a final CR rate of 87%. The most common toxicity with ⁹⁰Y-ibritumomab tiuxetan was hematologic, and grade 3 or 4 infections occurred in 8% of patients.

Conclusion Consolidation of first remission with ⁹⁰Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.

published online ahead of print atwww.jco.org on October 13, 2008

Supported by Bayer Schering Pharma AG, Berlin, Germany.

Presented in part at the 49th Annual Meeting of the American Society of Hematology, December 8-11, 2007, Atlanta, GA.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

• High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
  Liliana Devizzi, Anna Guidetti, Corrado Tarella, Michele Magni, Paola Matteucci, Ettore Seregni, Carlo Chiesa, Emilio Bombardieri, Massimo Di Nicola, Carmelo Carlo-Stella, and Alessandro M. Gianni
  JCO 2008 26: 5175-5182 [Abstract] [Full Text]

Related Editorial

• Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas
  Oliver W. Press
  JCO 2008 26: 5147-5150 [Full Text]

This article has been cited by other articles:

				A. B. Delaloye, C. Antonescu, T. Louton, J. Kuhlmann, and A. Hagenbeek Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial J. Nucl. Med., November 1, 2009; 50(11): 1837 - 1843. [Abstract] [Full Text] [PDF]

				A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory Introduction Oncologist, October 1, 2009; 14(suppl_2): 1 - 3. [Full Text] [PDF]

				S. A. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, and M. Dreyling Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 4 - 16. [Abstract] [Full Text] [PDF]

				F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF]

				A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory Summary Oncologist, October 1, 2009; 14(suppl_2): 52 - 54. [Full Text] [PDF]

				T. Illidge and Y. Du When is a predose a dose too much? Blood, June 4, 2009; 113(23): 6034 - 6035. [Full Text] [PDF]

				M. Dreyling and On behalf of the ESMO Guidelines Working Group Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv119 - iv120. [Full Text] [PDF]

				R. M. Sharkey, O. W. Press, and D. M. Goldenberg A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy Blood, April 23, 2009; 113(17): 3891 - 3895. [Abstract] [Full Text] [PDF]

				H. Hochster, E. Weller, R. D. Gascoyne, T. M. Habermann, L. I. Gordon, T. Ryan, L. Zhang, N. Colocci, S. Frankel, and S. J. Horning Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study J. Clin. Oncol., April 1, 2009; 27(10): 1607 - 1614. [Abstract] [Full Text] [PDF]

				A. Hagenbeek Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand? J. Clin. Oncol., April 1, 2009; 27(10): 1540 - 1542. [Full Text] [PDF]

				T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy Blood, February 12, 2009; 113(7): 1412 - 1421. [Abstract] [Full Text] [PDF]

				Prolonging Treatment Response in Follicular Lymphoma Journal Watch Oncology and Hematology, November 25, 2008; 2008(1125): 2 - 2. [Full Text]

				O. W. Press Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas J. Clin. Oncol., November 10, 2008; 26(32): 5147 - 5150. [Full Text] [PDF]